NexgenRx Inc.

TSX VENTURE : NXG


NexgenRx Inc.

December 13, 2013 16:01 ET

NexgenRx Extends Debenture Maturity Date

TORONTO, ONTARIO--(Marketwired - Dec. 13, 2013) - NEXGENRX INC. (TSX VENTURE:NXG) ("NexgenRx" or the "Corporation") announces that it has agreed to further extend the maturity date of its currently outstanding convertible debenture (the "Debenture"). The Debenture was issued in April 2012 in the principal amount of $500,000 and was set to expire on November 26, 2013. The Debenture was recently amended to extend the maturity date to December 12, 2013 and to amend the conversion price from $0.30 to $0.20 per common share. The maturity date has been further extended to June 12, 2015. The TSX Venture Exchange has approved this amendment to the terms of the Debenture.

About NexgenRx

NexgenRx is a growing health benefits management company engaged in the design, management and administration of health benefit plans offered by employers and other plan sponsors for the benefit of their employees and plan members. More information on NexgenRx can be found at www.nexgenrx.com.

Caution Regarding Forward-Looking Statements - This news release contains certain forward looking statements, including statements regarding the business and anticipated financial performance of the Corporation. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

Contact Information

  • Ronald C. Loucks
    NexgenRx Inc.
    President and CEO
    416.695.3393 x801

    Taba Merrikh
    NexgenRx Inc.
    Director of Finance
    416-695-3393x803